Cross-topic event
Life Biosciences ER-100: First Human Dosing of OSK Epigenetic Reprogramming Gene Therapy Enters Phase 1
Jun 10, 20262 reports
Jun 10, 2026
Sciencedesk view
Life Biosciences ER-100: First Human Dosing of OSK Epigenetic Reprogramming Gene Therapy Enters Phase 1
Per Euronews on June 10, 2026, Boston-based Life Biosciences announced the first human has received ER-100 (AAV2-OSK) — the first epigenetic "cellular rejuvenat…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
First-in-Human Dosing for Life Biosciences' Cellular "Rejuvenation" Gene Therapy ER-100
Per Euronews and Life Biosciences on June 9–10, Boston-based Life Biosciences dosed the first participant in a Phase 1 trial of ER-100 (AAV2-OSK), using control…
READ THE DAY'S DIGEST →